WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005105843) HIV PROTEASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/105843    International Application No.:    PCT/DK2005/000296
Publication Date: 10.11.2005 International Filing Date: 29.04.2005
IPC:
C07K 5/06 (2006.01), C07K 14/81 (2006.01), A61P 31/18 (2006.01), A61K 38/05 (2006.01), A61K 38/55 (2006.01)
Applicants: ARPIDA A/S [DK/DK]; Vesterbrogade 188, DK-1800 Frederiksberg C (DK) (For All Designated States Except US).
JENSEN, Christian, Eeg [DK/DK]; (DK) (For US Only).
BONDEBJERG, Jon [DK/DK]; (DK) (For US Only).
NÆRUM, Lars [DK/DK]; (DK) (For US Only)
Inventors: JENSEN, Christian, Eeg; (DK).
BONDEBJERG, Jon; (DK).
NÆRUM, Lars; (DK)
Agent: ALBIHNS A/S; H.C. Andersens Boulevard 49, DK-1553 Copenhagen V (DK)
Priority Data:
PA 2004 00684 30.04.2004 DK
60/567,969 03.05.2004 US
Title (EN) HIV PROTEASE INHIBITORS
(FR) INHIBITEURS DE VIH PROTEASE
Abstract: front page image
(EN)Phosphinate compounds of general formula (I) or pharmaceutically acceptable salts or esters thereof, that are capable of potently inhibiting proteases such as, e.g., metallo proteases or aspartate proteases, especially HIV protease including HIV-1 proteases. A compound of the invention is therefore useful as an active substance in the treatment of HIV related diseases such as AIDS.
(FR)Cette invention se rapporte à des composés de phosphinate représentés par la formule générale (I) ou à des sels ou esters de ces composés, acceptables sur le plan pharmaceutique, qui sont capables de produire un puissant effet inhibiteur contre les protéases, telles que notamment les métalloproteases ou les aspartate protéases, en particulier la VIH protéase et notamment les VIH-1 protéases. Un tel composé est par conséquent utile comme substance active dans le traitement des maladies liées au VIH, telles que le sida.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)